What type of therapy does Benralizumab (Fasenra) utilize?

Benralizumab (Fasenra) is a monoclonal antibody specifically designed to target interleukin-5 (IL-5). This therapy is utilized primarily for the treatment of severe asthma in patients with an eosinophilic phenotype. IL-5 plays a crucial role in the growth, differentiation, recruitment, activation, and survival of eosinophils, which are a type of white blood cell that, in excessive numbers, contribute to inflammation and asthma symptoms. By targeting IL-5, Benralizumab effectively reduces eosinophil levels in the blood and tissues, leading to improved respiratory function and reduced frequency of asthma exacerbations.

The other options focus on different interleukins or factors involved in immune responses. For instance, anti-IL6 would target interleukin-6, which is involved in inflammatory processes but is not specifically related to eosinophil activity. Anti-TNF (tumor necrosis factor) therapies are utilized in autoimmune conditions by inhibiting a different part of the inflammatory cascade. Anti-IL4 and its associated pathway also play roles in allergic responses but do not directly target eosinophils like IL-5 does. Thus, the selection of anti-IL5 for Benral